Topical Antibiotic Treatment in Dermatology
Abstract
:1. Introduction
2. Methods
3. Discussion
3.1. Amikacin
3.2. Azelaic Acid
3.3. Benzoyl Peroxide
3.4. Clindamycin
3.5. Dapsone
3.6. Fusidic Acid
3.7. Gentamicin
3.8. Metronidazole
3.9. Minocycline
3.10. Mupirocin
3.11. Neomycin
3.12. Ozenoxacin
3.13. Retapamulin
3.14. Silver Sulfadiazine
4. Conclusions
5. Future Directions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Stevens, D.L.; Bisno, A.L.; Chambers, H.F.; Dellinger, E.P.; Goldstein, E.J.; Gorbach, S.L.; Hirschmann, J.V.; Kaplan, S.L.; Montoya, J.G.; Wade, J.C. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2014, 59, e10–e52. [Google Scholar] [CrossRef] [Green Version]
- Gelmetti, C. Local antibiotics in dermatology. Dermatol. Ther. 2008, 21, 187–195. [Google Scholar] [CrossRef] [PubMed]
- La Torre, F.; Nicolai, A.P. Amikacin gel administration in the treatment of peristomal dermatitis. Drugs Exp. Clin. Res. 1998, 24, 153–157. [Google Scholar] [PubMed]
- Schulte, B.C.; Wu, W.; Rosen, T. Azelaic Acid: Evidence-based Update on Mechanism of Action and Clinical Application. J. Drugs Dermatol. 2015, 14, 964–968. [Google Scholar] [PubMed]
- Nazzaro-Porro, M.; Passi, S.; Picardo, M.; Breathnach, A.S.; Zina, G. L’acido azelaico nella terapia dell’acne [Azelaic acid in the treatment of acne]. G. Ital. Dermatol. Venereol. 1989, 124, 175–184. [Google Scholar]
- Gupta, A.K.; Gover, M.D. Azelaic acid (15% gel) in the treatment of acne rosacea. Int. J. Dermatol. 2007, 46, 533–538. [Google Scholar] [CrossRef] [PubMed]
- Okamoto, K.; Kanayama, S.; Ikeda, F.; Fujikawa, K.; Fujiwara, S.; Nozawa, N.; Mori, S.; Matsumoto, T.; Hayashi, N.; Oda, M. Broad spectrum in vitro microbicidal activity of benzoyl peroxide against microorganisms related to cutaneous diseases. J. Dermatol. 2021, 48, 551–555. [Google Scholar] [CrossRef]
- Matin, T.; Goodman, M.B. Benzoyl Peroxide; StatPearls: Treasure Island, FL, USA, 2022. [Google Scholar]
- Bandyopadhyay, D. Topical Antibacterials in Dermatology. Indian J. Dermatol. 2021, 66, 117–125. [Google Scholar] [CrossRef]
- Spizek, J.; Rezanka, T. Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications. Biochem. Pharmacol. 2017, 133, 20–28. [Google Scholar] [CrossRef]
- Guay, D.R.P. Topical clindamycin in the management of acne vulgaris. Expert Opin. Pharmacother. 2007, 8, 2625–2664. [Google Scholar] [CrossRef]
- Braathen, L.R. Topical clindamycin versus oral tetracycline and placebo in acne vulgaris. Scand. J. Infect. Dis. Suppl. 1984, 43, 71–75. [Google Scholar]
- Resh, W.; Stoughton, R.B. Topically applied antibiotics in acne vulgaris: Clinical Response and Suppression Corynebacterium acnes in Open Comedones. Arch. Dermatol. 1976, 112, 182. [Google Scholar] [CrossRef]
- Sheehan-Dare, R.A.; Papworth-Smith, J.; Cunliffe, W.J. A double-blind comparison of topical clindamycin and oral minocycline in the treatment of acne vulgaris. Acta Derm. Venereol. 1990, 70, 534–537. [Google Scholar] [PubMed]
- Clemmensen, O.J. Topical treatment of hidradenitis suppurativa with clindamycin. Int. J. Dermatol. 1983, 22, 325–328. [Google Scholar] [CrossRef] [PubMed]
- Alikhan, A.; Sayed, C.; Alavi, A.; Alhusayen, R.; Brassard, A.; Burkhart, C.; Crowell, K.; Eisen, D.B.; Gottlieb, A.B.; Hamzavi, I.; et al. North American Clinical Management Guidelines for hidradenitis suppurativa: A publication from the United States and Canadian hidradenitis suppurativa foundations. J. Am. Acad. Dermatol. 2019, 81, 91–101. [Google Scholar] [CrossRef] [Green Version]
- Jemec, G.B.; Wendelboe, P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J. Am. Acad. Dermatol. 1998, 39, 971–974. [Google Scholar] [CrossRef]
- Fischer, A.H.; Haskin, A.; Okoye, G.A. Patterns of antimicrobial resistance in lesions of Hidradenitis Suppurativa. J. Am. Acad. Dermatol. 2017, 76, 309–313. [Google Scholar] [CrossRef] [PubMed]
- Aoki, S.; Nakase, K.; Nakaminami, H.; Wajima, T.; Hayashi, N.; Noguchi, N. Transferable Multidrug-Resistance Plasmid Carrying a Novel Macrolide-Clindamycin Resistance Gene, erm(50), in Cutibacterium acnes. Antimicrob. Agents Chemother. 2020, 64, e01810-19. [Google Scholar] [CrossRef] [PubMed]
- Assefa, M. Inducible Clindamycin-Resistant Staphylococcus aureus Strains in Africa: A Systematic Review. Int. J. Microbiol. 2022, 2022, 1835603. [Google Scholar] [CrossRef]
- Murphy, P.B.; Bistas, K.G.; Le, J.K. Clindamycin-StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
- Milstone, E.B. Pseudomembranous colitis after topical application of clindamycin. Arch. Dermatol. 1981, 117, 154. [Google Scholar] [CrossRef] [PubMed]
- Parry, M.F. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch. Dermatol. 1986, 122, 583. [Google Scholar] [CrossRef]
- Temiz, S.A.; Daye, M. Dapsone for the treatment of acne vulgaris: Do the risks outweigh the benefits? Cutan. Ocul. Toxicol. 2022, 41, 60–66. [Google Scholar] [CrossRef]
- Jarratt, M.T.; Bucko, A.D.; Grekin, S.K.; Berlin, J.M.; Bukhalo, M.; Weiss, J.S.; Berk, D.R.; Chang-Lin, J.E.; Lin, V.; Kaoukhov, A. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: First of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J. Drugs Dermatol. 2016, 15, 553–561. [Google Scholar]
- Eichenfield, L.F.; Lain, T.; Frankel, E.H.; Jones, T.M.; Chang-Lin, J.E.; Berk, D.R.; Ruan, S.; Kaoukhov, A. Efficacy and safety of once-daily dapsone gel 7.5% for treatment of adolescents and adults with acne vulgaris: Second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. J. Drugs Dermatol. 2016, 15, 962–969. [Google Scholar] [PubMed]
- Swartzentruber, G.S.; Yanta, J.H.; Pizon, A.F. Methemoglobinemia as a complication of topical dapsone. N. Engl. J. Med. 2015, 372, 491–492. [Google Scholar] [CrossRef] [Green Version]
- Koripella, R.K.; Chen, Y.; Peisker, K.; Koh, C.S.; Selmer, M.; Sanyal, S. Mechanism of elongation factor-G-mediated fusidic acid resistance and fitness compensation in Staphylococcus aureus. J. Biol. Chem. 2012, 287, 30257–30267. [Google Scholar] [CrossRef] [Green Version]
- Wilkinson, J.D. Fusidic acid in dermatology. Br. J. Dermatol. 1998, 139, 37–40. [Google Scholar] [CrossRef] [PubMed]
- Fernandes, P. Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections. Cold Spring Harb. Perspect. Med. 2016, 6, a025437. [Google Scholar] [CrossRef]
- Bonamonte, D.; Belloni Fortina, A.; Neri, L.; Patrizi, A. Fusidic acid in skin infections and infected atopic eczema. G. Ital. Dermatol. Venereol. 2014, 149, 453–459. [Google Scholar]
- Schöfer, H.; Simonsen, L. Fusidic acid in dermatology: An updated review. Eur. J. Dermatol. 2010, 20, 6–15. [Google Scholar] [CrossRef]
- Buechler, C.R.; Daveluy, S.D. A Comprehensive Guide to Hidradenitis Suppurative-Topical Therapeutics; Elsevier: Philadelphia, PA, USA, 2021. [Google Scholar]
- Aronson, J.K. Fusidic Acid. In The International Encyclopedia of Adverse Drug Reactions and Interactions, 16th ed.; Elsevier: Amsterdam, The Netherlands, 2016; pp. 475–477. [Google Scholar]
- Gentamicin. Br. Med. J. 1967, 1, 158–159. [CrossRef] [Green Version]
- Bertolotti, A.; Sbidian, E.; Join-Lambert, O.; Bourgault-Villada, I.; Moyal-Barracco, M.; Perrot, P.; Jouan, N.; Yordanov, Y.; Sidorkiewicz, S.; Chazelas, K.; et al. Guidelines for the management of hidradenitis suppurativa: Recommendations supported by the Centre of Evidence of the French Society of Dermatology. Br. J. Dermatol. 2021, 184, 963–965. [Google Scholar] [CrossRef] [PubMed]
- McClellan, K.J.; Noble, S. Topical Metronidazole. Am. J. Clin. Dermatol. 2000, 1, 191–199. [Google Scholar] [CrossRef] [PubMed]
- Bleicher, P.A.; Charles, J.H.; Sober, A.J. Topical metronidazole therapy for rosacea. Arch. Dermatol. 1987, 123, 609–614. [Google Scholar] [CrossRef]
- Nielsen, P.G. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br. J. Dermatol. 1983, 108, 327–332. [Google Scholar] [CrossRef] [PubMed]
- Highlights of Prescribing Information ZILXI. ZILXI (Minocycline) Topical Foam. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213690s000lbl.pdf (accessed on 2 January 2023).
- Highlights of Prescribing Information AMZEEQ. AMZEEQ (Minocycline) Topical Foam. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212379s000lbl.pdf (accessed on 2 January 2023).
- Gold, L.S.; Del Rosso, J.Q.; Kircik, L.; Bhatia, N.D.; Hooper, D.; Nahm, W.K.; Stuart, I. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials. J. Am. Acad. Dermatol. 2020, 82, 1166–1173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paik, J. Topical Minocycline Foam 4%: A Review in Acne Vulgaris. Am. J. Clin. Dermatol. 2020, 21, 449–456. [Google Scholar] [CrossRef]
- Kircik, L.; Del Rosso, J.Q.; Weiss, J.S.; Stakias, V.; London, A.; Keynan, R.; Hazot, Y.; Elliott, R.; Stuart, I. Formulation and Profile of FMX101 4% Minocycline Topical Foam for the Treatment of Acne Vulgaris. J. Clin. Aesthet. Dermatol. 2020, 13, 14–21. [Google Scholar]
- Information for Patients. Discover AMZEEQ|AMZEEQ® (Minocycline) Topical Foam, 4%. Available online: https://www.amzeeq.com/about-amzeeq (accessed on 9 January 2023).
- Tucaliuc, A.; Blaga, A.C.; Galaction, A.I.; Cascaval, D. Mupirocin: Applications and production. Biotechnol. Lett. 2019, 41, 495–502. [Google Scholar] [CrossRef]
- Food and Drug Administration. Bactroban Cream. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf (accessed on 2 January 2023).
- Patel, J.B.; Gorwitz, R.J.; Jernigan, J.A. Mupirocin Resistance. Clin. Infect. Dis. 2009, 49, 935–941. [Google Scholar] [CrossRef] [Green Version]
- Margaret, M.G.A.; Jo, J.-H.; Kong, H.H. Antibiotic Stewardship in Dermatology-Reducing the Risk of Prolonged Antimicrobial Resistance in Skin. JAMA Dermatol. 2022, 158, 989–991. [Google Scholar]
- Nguyen, R.; Khanna, N.R.; Safadi, A.O.; Sun, Y. Bacitracin Topical; StatPearls: Treasure Island, FL, USA, 2022. [Google Scholar]
- Shatri, G.; Tadi, P. Polymyxin; StatPearls: Treasure Island, FL, USA, 2022. [Google Scholar]
- Fàbrega, A.; Madurga, S.; Giralt, E.; Vila, J. Mechanism of action of and resistance to quinolones. Microb. Biotechnol. 2009, 2, 40–61. [Google Scholar] [CrossRef] [Green Version]
- Rosen, T.; Albareda, N.; Rosenberg, N.; Alonso, F.G.; Roth, S.; Zsolt, I.; Hebert, A.A. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients with Impetigo: A Randomized Clinical Trial. JAMA Dermatol. 2018, 154, 806–813. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Highlights of Prescribing Information XEPI (Ozenoxacin) Topical Cream. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208945lbl.pdf (accessed on 1 January 2023).
- Paukner, S.; Riedl, R. Pleuromutilins: Potent drugs for resistant bugs—Mode of action and resistance. Cold Spring Harbor Perspect. Med. 2016, 7, a027110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coutinho, B. Retapamulin (Altabax) 1% Topical Ointment for the Treatment of Impetigo. Am. Fam. Physician 2007, 76, 1537–1541. [Google Scholar]
- Patel, A.B.; Lighter, J.; Fulmer, Y.; Copin, R.; Ratner, A.J.; Shopsin, B. Retapamulin activity against pediatric strains of mupirocin-resistant methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 2021, 40, 637–638. [Google Scholar] [CrossRef]
Acne Vulgaris | Rosacea | Hidradenitis Suppurativa | Secondarily-Infected Dermatitis | Skin and Soft-Tissue Infection (ex: Impetigo) |
---|---|---|---|---|
Azelaic Acid | Azelaic acid | Clindamycin | Fusidic Acid | Amikacin |
Benzoyl Peroxide | Minocycline | Mupirocin | Clindamycin | |
Clindamycin | Metronidazole | Fusidic acid | ||
Dapsone | Mupirocin | |||
Minocycline | Ozenoxacin | |||
Retapamulin |
Brand Name | Generic Name | Preparation | Dosage | Approved Indications | Age for Use | Bacterial Activity |
---|---|---|---|---|---|---|
Azelex; Finacea | Azelaic Acid | Cream, Foam, Gel | 15% (Gel/Foam) 20% (Cream) | Acne Vulgaris, Rosacea | ≥12 years | Gram + |
Benzac; Benzefoam; Benzepro; Clean and Clear; Clearasil | Benzoyl Peroxide | Cream, Foam, Gel, Solution, Lotion | 2.5–10% | Acne Vulgaris | ≥7 years | Gram + |
Cleocin; Cleocin-T; Clindacin ETZ; Clindacin Pac; Clindagel; Clindesse; Evoclin | Clindamycin | Cream, Foam, Gel, Lotion, Solution, Swab | 1%, 2% | Acne Vulgaris | ≥12 years | Gram +/− |
Aczone | Dapsone | Gel | 5%, 7.5% | Acne Vulgaris | ≥9 years (Gel 7.5%) ≥12 years (Gel 5%) | Gram +/− |
Fucidin (Available in Canada; not available in the US) | Fusidic Acid | Cream, Ointment | 2% | Skin/Soft Tissue Infections | ≥5 years | Gram + |
Garamycin | Gentamicin | Cream, Ointment | 0.1% | Primary/Secondary Skin Infections | ≥1 year | Gram − |
MetroCream; Metrogel; MetroLotion; Noritate; Rosadan | Metronidazole | Cream, Gel, Lotion | 0.75%, 1% | Rosacea | ≥18 years | Anaerobes |
Amzeeq; Zilxi | Minocycline | Foam | 1.5%, 4% | Acne Vulgaris, Rosacea | ≥18 years (Foam 1.5%) ≥9 years (Foam 4%) | Gram +/− |
Bactroban; Centany; Pirnuo | Mupirocin | Cream, Ointment | 2% | Impetigo, Secondarily Infected Skin Lesions | ≥2 months | Gram + |
Neosporin; Triple Antibiotic | Neomycin/Bacitracin/ Polymyxin B | Cream, Ointment | 0.5% | Secondary Skin Infections | ≥2 years | Gram − |
Xepi | Ozenoxacin | Cream | 1% | Impetigo | ≥2 months | Gram + > Gram − |
Altabax; Altargo | Retapamulin | Ointment | 1% | Impetigo | ≥9 months | Gram + |
Silvadene; SSD; Thermazene | Silver Sulfadiazine | Cream | 1% | Prevention/Treatment of Wound Sepsis in Second- and Third-Degree Burns | >2 months | Gram +/− |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dallo, M.; Patel, K.; Hebert, A.A. Topical Antibiotic Treatment in Dermatology. Antibiotics 2023, 12, 188. https://doi.org/10.3390/antibiotics12020188
Dallo M, Patel K, Hebert AA. Topical Antibiotic Treatment in Dermatology. Antibiotics. 2023; 12(2):188. https://doi.org/10.3390/antibiotics12020188
Chicago/Turabian StyleDallo, Matthew, Kavina Patel, and Adelaide A. Hebert. 2023. "Topical Antibiotic Treatment in Dermatology" Antibiotics 12, no. 2: 188. https://doi.org/10.3390/antibiotics12020188